Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

Authors: Leili Gao, Byung‐Wan Lee, Manoj Chawla, Joshua Kim, Li Huo, Liying Du, Yan Huang, Linong Ji - Nature Medicine 2023 cited by 95